Simultaneous determination of cyclophosphamide, ifosfamide, doxorubicin, epirubicin and daunorubicin in human urine using high-performance liquid chromatography/electrospray ionization tandem mass spectrometry: bioanalytical method validation.
about
Sampling and mass spectrometric analytical methods for five antineoplastic drugs in the healthcare environmentIdentification of Knowledge Gaps Regarding Healthcare Workers' Exposure to Antineoplastic Drugs: Review of Literature, North America versus EuropeHazardous drug residue on exterior vial surfaces: evaluation of a commercial manufacturing processA review of high performance liquid chromatographic-mass spectrometric urinary methods for anticancer drug exposure of health care workersDispersive solid-phase extraction procedure coupled to UPLC-ESI-MS/MS analysis for the simultaneous determination of thirteen cytotoxic drugs in human urine.Antineoplastic drugs and their analysis: a state of the art review.Occurrence of cyclophosphamide and epirubicin in wastewaters by direct injection analysis-liquid chromatography-high-resolution mass spectrometry.Biological monitoring of nurses exposed to doxorubicin and epirubicin by a validated liquid chromatography/fluorescence detection method.Pilot study comparing the efficacy of two cleaning techniques in reducing environmental contamination with cyclophosphamide.Occupational exposure to antineoplastic drugs in seven Italian hospitals: the effect of quality assurance and adherence to guidelines.Surface-modified solid lipid nanoparticulate formulation for ifosfamide: development and characterization.Genetic background influences susceptibility to chemotherapy-induced hematotoxicity.Wipe sampling procedure coupled to LC-MS/MS analysis for the simultaneous determination of 10 cytotoxic drugs on different surfaces.Enhancement of oral bioavailability of doxorubicin through surface modified biodegradable polymeric nanoparticles.
P2860
Q23914149-6EDD2919-D2E8-4B09-84D4-978BD0E8A6F1Q27003871-82B97A58-BDCA-4233-AFD5-CE71544FB659Q28388219-F863EAE9-0F20-4CF3-B807-51C2F36F319DQ32944296-91D4A049-3920-4072-B88C-44C83A09F25AQ35893243-5F4763D1-DE6E-46BE-A3E4-18C279C3703BQ39339684-E06AEEF6-7C30-4E1E-8F42-9129CD6F60E3Q40024426-4B805BE1-0F0C-4286-9E7A-AC25044FC7A8Q43064194-E222F2FC-AD42-4E19-B11B-6E4536458C26Q43179437-5FE7F784-03E1-47FF-B064-A09F1F266861Q44449596-460B9D12-AA27-45D7-99BD-1761D048332FQ46218236-DCDF3644-9CE0-4ED3-BAC2-FBDB6F6E48A2Q47094464-DAA38FE1-3AED-4C5F-B911-E070112EA05FQ51025294-133DA42A-6E7C-4DEB-B8E3-211CB4CEF3DBQ55431512-97F1BB47-6F49-438E-92A6-C7550A0C220D
P2860
Simultaneous determination of cyclophosphamide, ifosfamide, doxorubicin, epirubicin and daunorubicin in human urine using high-performance liquid chromatography/electrospray ionization tandem mass spectrometry: bioanalytical method validation.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Simultaneous determination of ...... oanalytical method validation.
@en
Simultaneous determination of ...... oanalytical method validation.
@nl
type
label
Simultaneous determination of ...... oanalytical method validation.
@en
Simultaneous determination of ...... oanalytical method validation.
@nl
prefLabel
Simultaneous determination of ...... oanalytical method validation.
@en
Simultaneous determination of ...... oanalytical method validation.
@nl
P2093
P2860
P356
P1476
Simultaneous determination of ...... ioanalytical method validation
@en
P2093
Claudio Minoia
Cristina Teragni
Emanuela Leoni
Guido Poggi
Paola Rinaldi
P2860
P304
P356
10.1002/RCM.3657
P577
2008-09-01T00:00:00Z